Webb Alastair J S, Feakins Karolina, Lawson Amy, Stewart Catriona, Thomas James, Llwyd Osian
Department of Brain Sciences, Imperial College London, London, UK.
Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford, Oxford, UK.
Int J Stroke. 2025 Jul 10:17474930251360093. doi: 10.1177/17474930251360093.
Vasodilating drugs targeting the endothelium could reduce long-term harms due to cerebral small vessel disease (cSVD) but there are no commonly accepted methods to measure short-term disease activity or drug response. In the OxHARP clinical trial, we determined the most sensitive physiological markers of treatment response to sildenafil versus placebo on either transcranial ultrasound (TCD) or magnetic resonance imaging (MRI), and their validity compared to disease severity and other measures of other physiological mechanisms.
In the OxHARP double-blind, randomized, placebo-controlled crossover trial we measured aortic blood pressure, mean flow velocity (MFV), cerebral pulsatility, cerebrovascular conductance index (CVCi = MFV/aortic mean BP), cerebral perfusion (pcASL-MRI) and cerebrovascular reactivity to inhaled CO2 on TCD (CVR-TCD) and MRI in white (CVR-WM), gray (CVR-GM) and white matter hyperintensities (CVR-WMH). Effects of 3 weeks of sildenafil were compared to placebo. Validity of markers were determined by between-visit repeatability (intraclass correlation coefficient (ICC)); associations with CVR-TCD, CVR-WMH and CVR-GM; associations with other markers; the magnitude of response, and sensitivity, to sildenafil.
In 69 participants, repeatability was greatest for MFV, pulsatility, CVCi and CVR-WMH (ICC > 0.8), very good for CVR-TCD and GM-perfusion (ICC > 0.7), and good for CVR-GM (ICC > 0.6). CVR-TCD was associated with CVR on MRI (CVR-WMH: r = 0.12, p = 0.02; CVR-GM: r = 0.22, p = 0.001), while blood flow measures on TCD (MFV, CVCi) were associated with CVR-TCD and perfusion-MRI (all p < 0.05). All markers were associated with WMH volume and improved by sildenafil, but CVCi was most sensitive, requiring only 20 patients for a crossover trial at 80% power, compared to 26 for GM-perfusion or 84 for CVR-GM.
Multiple markers were associated with cSVD, but no single marker reflected all physiological drug effects. CVCi and gray matter perfusion on MRI were the most sensitive markers of disease activity and drug response, although CVR indices may be more specific for endothelial dysfunction.
靶向内皮的血管舒张药物可能会减少脑小血管疾病(cSVD)所致的长期损害,但目前尚无普遍认可的方法来测量短期疾病活动或药物反应。在OxHARP临床试验中,我们确定了在经颅超声(TCD)或磁共振成像(MRI)上,西地那非与安慰剂相比治疗反应最敏感的生理标志物,以及它们与疾病严重程度和其他生理机制测量指标相比的有效性。
在OxHARP双盲、随机、安慰剂对照交叉试验中,我们测量了主动脉血压、平均流速(MFV)、脑搏动性、脑血管传导指数(CVCi = MFV/主动脉平均血压)、脑灌注(pcASL-MRI)以及TCD上对吸入二氧化碳的脑血管反应性(CVR-TCD),并在白质(CVR-WM)、灰质(CVR-GM)和白质高信号(CVR-WMH)上进行了MRI测量。将西地那非3周的效果与安慰剂进行比较。通过访间重复性(组内相关系数(ICC))确定标志物的有效性;与CVR-TCD、CVR-WMH和CVR-GM的相关性;与其他标志物的相关性;对西地那非的反应幅度和敏感性。
在69名参与者中,MFV、搏动性、CVCi和CVR-WMH的重复性最好(ICC>0.8),CVR-TCD和灰质灌注的重复性非常好(ICC>0.7),CVR-GM的重复性良好(ICC>0.6)。CVR-TCD与MRI上的CVR相关(CVR-WMH:r = 0.12,p = 0.02;CVR-GM:r = 0.22,p = 0.001),而TCD上的血流测量指标(MFV、CVCi)与CVR-TCD和灌注MRI相关(所有p<0.05)。所有标志物均与WMH体积相关且西地那非可使其改善,但CVCi最敏感,在80%检验效能的交叉试验中仅需20例患者,而灰质灌注需要26例,CVR-GM需要84例。
多个标志物与cSVD相关,但没有单一标志物能反映所有生理药物效应。MRI上的CVCi和灰质灌注是疾病活动和药物反应最敏感的标志物,尽管CVR指数可能对内皮功能障碍更具特异性。